INVESTOR RELATIONS
Scientific Posters and Presentations
Icotrokinra (JNJ-77242113):
For posters and presentations relating to icotrokinra (JNJ-77242113), please refer to the link here (link and site maintained by Johnson & Johnson):
Rusfertide (PTG-300):
Results from VERIFY, An International, Randomized Phase 3 Double-blind Placebo-controlled Study of Rusfertide (First-In-Class Hepcidin Mimetic) for Treatment of Polycythemia Vera (PV)
VERIFY, A Phase 3 Placebo-Controlled Study Investigating Rusfertide With Current Standard of Care Therapy in Patients With Polycythemia Vera
Adaptation of ASCO’25 Phase 3 VERIFY Plenary Presentation
Final Results from the Phase 2 REVIVE Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV)
Updated Long-Term Results from the Phase 2 REVIVE Study Investigating the Hepcidin Mimetic Rusfertide in Polycythemia Vera Patients: Hematocrit Control and Therapeutic Phlebotomy Frequency
Pharmacokinetics, Pharmacodynamics and Safety of Rusfertide, a Hepcidin Mimetic, in Subjects with Hepatic Impairment and in Subjects with Renal Impairment
DISCOVERY:
Iron Restricted Erythropoiesis under Hepcidin Mimetic Treatment (PN23114) Improves Disease Parameters in a Mouse Model for Sickle Cell Disease
Rusfertide Analog-PN23114 as a Hepcidin Mimetic Provides Efficacy Benefits in Conjunction with Phlebotomy in Mouse Model for Hereditary Hemochromatosis (Oral Presentation)
Regulation of Iron Homeostasis and Efficacy of Rusfertide Analog Peptide in a Mouse Model for Polycythemia Vera
PN-881:
PN-881: First-in-class oral peptide targeting the IL-17 pathway
PN-881: First-in-class oral peptide targeting the IL-17 pathway
PEER-REVIEWED MANUSCRIPTS
Icotrokinra (JNJ-77242113):
Knight B, et al. Dermatol Ther (Heidelb). 2025;15(9):2495-520
Ferris LK, et al. J Am Acad Dermatol. 2025 Mar;92(3):495-502
Stein Gold L, et al. Adv Ther. 2025;42(7):3158-172
Fourie AM, et al. Sci Rep. 2024;14(1):17515
Bissonnette R, et al. N Engl J Med. 2024;390(6):510-21
Rusfertide (PTG-300):
Kremyanskaya M, et al. N Engl J Med. 2024;390(8):723-35
Modi NB, et al. Clin Pharmacol Drug Dev. 2025;14(4):311-23
Modi NB, et al. Drugs R D. 2024;24(4):539-52
Kuykendall AT, et al. Clin Lymphoma Myeloma Leuk. 2024;24(8):512-22
Modi NB, et al. Eur J Haematol. 2024;113(3):340-50
Kowdley KV, et al. Lancet Gastroenterol Hepatol. 2023;8(12):1118-28
PN-943:
Modi NB et al. Clin Pharmacol Drug Dev. 2021;10(11):1263-78
PTG-100:
Sandborn WJ, et al. Gastroenterology 2021;161:1853-64